Olaparib induced aplastic anemia in a patient with castrate resistant prostate cancer: A case report

Olaparib induced aplastic anemia in a patient with castrate resistant prostate cancer: A case report

Olaparib is (ADP‐ribose) polymerase inhibitor (PARPi), which stops the repair of single-stranded DNA breaks. This leads to the death of cancer cells with BRCA1/BRCA2 mutations or homologous recombination deficiency. Since being approved by the FDA in 2023 for treating castrate-resistant prostate can...

Full description

Bibliographic Details
Main Authors: Elrazi A Ali, Monika Jain, Akriti Pokhrel, Unni Mooppan, Jen chin Wang
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:Leukemia Research Reports
Subjects:
Aplastic anemia
Olaparib
Prostate cancer
Pancytopenia
Online Access:http://www.sciencedirect.com/science/article/pii/S2213048924000633

Internet

http://www.sciencedirect.com/science/article/pii/S2213048924000633

Similar Items